MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Incyte Corp

Ouvert

SecteurSoins de santé

58.51 0.39

Résumé

Variation du prix de l'action

24h

Actuel

Min

57.77

Max

59.02

Chiffres clés

By Trading Economics

Revenu

95M

201M

Ventes

39M

1.2B

P/E

Moyenne du Secteur

378.667

57.333

BPA

1.43

Marge bénéficiaire

17.071

Employés

2,617

EBITDA

145M

337M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+25.27% upside

Dividendes

By Dow Jones

Prochains Résultats

29 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-5.4B

11B

Ouverture précédente

58.12

Clôture précédente

58.51

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Incyte Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Alphabet, Intel, AppFolio

24 avr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 avr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 avr. 2025, 23:37 UTC

Actualités

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 avr. 2025, 23:36 UTC

Actualités

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 avr. 2025, 23:13 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 avr. 2025, 23:09 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 avr. 2025, 22:51 UTC

Actualités
Acquisitions, Fusions, Rachats

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 avr. 2025, 22:48 UTC

Actualités

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 avr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 avr. 2025, 22:38 UTC

Market Talk
Résultats

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 avr. 2025, 22:24 UTC

Résultats

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 avr. 2025, 22:24 UTC

Market Talk
Résultats

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 avr. 2025, 22:23 UTC

Résultats

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

24 avr. 2025, 22:11 UTC

Market Talk
Résultats

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 avr. 2025, 22:09 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 avr. 2025, 22:00 UTC

Market Talk
Résultats

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 avr. 2025, 21:39 UTC

Actualités

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 avr. 2025, 21:24 UTC

Actualités
Résultats

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 avr. 2025, 21:23 UTC

Actualités
Résultats

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 avr. 2025, 21:04 UTC

Résultats

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 avr. 2025, 21:03 UTC

Résultats

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 avr. 2025, 21:02 UTC

Résultats

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparaison

Variation de prix

Incyte Corp prévision

Objectif de Prix

By TipRanks

25.27% hausse

Prévisions sur 12 Mois

Moyen 73.87 USD  25.27%

Haut 92 USD

Bas 52 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

18 ratings

6

Achat

11

Maintien

1

Vente

Score Technique

By Trading Central

58.33 / 59.22Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation